Cornell University

Running trials

• Not yet recruiting

  Neuronavigated aiTBS for TRD

  NCT07329153· Source

• Recruiting

  Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  NCT07059091· Phase 2· Source

• Active, not recruiting

  A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

  NCT06384261· Phase 2· Source

• Recruiting

  Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

  NCT05230173· Source

• Active, not recruiting

  Metformin in Alzheimer's Dementia Prevention

  NCT04098666· Phase 2/3· Source

• Recruiting

  Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

  NCT04555161· Source

• Active, not recruiting

  A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

  NCT04194554· Phase 1/2· Source

• Active, not recruiting

  Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

  NCT03621644· Source

• Active, not recruiting

  Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis

  NCT03765450· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• COPD1 recruiting
• Crohn's disease1 recruiting
• Depression1 recruiting
• High blood pressure1 recruiting
• Pulmonary arterial hypertension1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer

  NCT05617040· Phase 1/2· Source

• Completed

  Phase 2 Study of DKN-01 in Colorectal Cancer

  NCT05480306· Phase 2· Source

• Completed

  Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

  NCT03258931· Phase 3· Source